

Hitting the Bull's Eye: Selective Targeting in Atopic Dermatitis

Friday, 17th November 2023 | 12:00–13:30 CET

Main Auditorium, Aula der Wissenschaften, Wollzeile 27a, A-1010
Vienna, Austria

IN-PERSON 

ACTIVITY OVERVIEW

International experts will engage in a fast-paced round robin Q&A about hot topics in IL-13 as related to atopic dermatitis. This will be followed by a review of the evolving story of type 2 immunity from a historical perspective, from discovery through to current understanding. Experts will then provide updates on IL-13 in non-lesional and lesional skin and ethnic, racial, and age similarities with respect to IL-13. The final presentation will discuss the latest science regarding mechanisms of IL-13 inhibition, mechanisms of action of approved and forthcoming IL-13 targeting drugs, and properties and attributes of each molecule.

TOPLINE AGENDA

Welcome and Introductions

Expert Quickfire

The Evolving Story of Type 2 Immunity


Updates on IL-13: The Key Cytokine in AD

What's New Regarding Mechanisms of IL-13 Inhibition?

Panel Discussion

Concluding Remarks/Final Thoughts





CHAIR



Emma Guttman, MD, PhD

Waldman Professor and Health System Chair
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York, United States

SPEAKERS



Patrick M. Brunner, MD

Associate Professor of Dermatology
Director of the Cutaneous Lymphoma Clinic
Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, New York, United States



Alan D. Irvine, MD

Professor of Dermatology
Trinity College Dublin
Dublin, Ireland

LEARNING OBJECTIVES

- Improve understanding of the role of IL-13 targeting in atopic dermatitis
- Describe various mechanisms of targeting IL-13 and the impact of each